On May 18, Parabilis Medicines announced a collaboration with Regeneron to develop therapies using the Helicon peptide platform. The agreement includes a $50 million upfront payment and a $75 million equity commitment from Regeneron. Potential milestone payments could reach up to $2.2 billion plus tiered royalties.
Mid-stage clinical trial data demonstrated that the company's experimental drug effectively shrinks vascular malformations and alleviates symptoms in patients.
Read the full storyHansa Biopharma secures an exclusive €115 million licensing deal with SERB to commercialize IDEFIRIX in Europe and MENA, providing a strategic path to profitability.
Parabilis Medicines partners with Regeneron in a deal featuring $125 million in upfront capital and up to $2.2 billion in milestones to develop intracellular therapies.
The acquisition aims to bolster the rare pulmonary disease pipeline through the LAM-001 program, supported by a private placement to fund clinical development.
BioMarin Pharmaceutical's experimental treatment met only one of two primary endpoints in a late-stage study, creating uncertainty over its regulatory path.
The UK MHRA has authorized VYJUVEK for dystrophic epidermolysis bullosa, marking the first genetic medicine approved in the country for this rare condition following successful launches in the US and Japan.
The biotech firm finalized its public offering after underwriters fully exercised their over-allotment option, securing funds to advance Phase 2 trials for its lead drug candidate.
The biotech firm aims to eliminate over $120 million in debt by exchanging 2027 convertible senior notes with the support of existing noteholders.